Results 141 to 150 of about 3,621 (185)

Preclinical pharmacology of milnacipran

International Clinical Psychopharmacology, 1996
Milnacipran (Ixel) is a new antidepressant which has been developed for its selective inhibition of both serotonin and noradrenaline reuptake and its lack of affinity for neurotransmitter receptors. It inhibits virtually equipotently the reuptake of serotonin and noradrenaline both in vitro and in vivo, as demonstrated by the antagonism of centrally ...
M, Briley, J F, Prost, C, Moret
openaire   +2 more sources

Fatal intoxication with milnacipran

Journal of Forensic and Legal Medicine, 2008
The antidepressant milnacipran is a double serotonin/noradrenalin reuptake inhibitor. The low reported incidence of intoxication indicates excellent tolerance in comparison with tricyclic and second generation antidepressants. We report a fatal intoxication associating milnacipran, at blood levels (femoral=21.5 mg/l, cardiac=20 mg/l) 40-fold higher ...
Laurent, Fanton, Fabien, Bévalot, Habdelhamid, Grait, Catherine, Le Meur, Yvan, Gaillard, Daniel, Malicier   +5 more
openaire   +2 more sources

Milnacipran

Drugs, 1998
Milnacipran is a cyclopropane derivative which acts by inhibiting noradrenaline (norepinephrine) and serotonin (5-hydroxytryptamine; 5-HT) reuptake at presynaptic sites; no postsynaptic receptor activity has been demonstrated. It is most commonly administered at a dosage of 50 mg twice daily for the treatment of major depressive disorder.
C M, Spencer, M I, Wilde
openaire   +2 more sources

Psychiatric comorbidities and use of milnacipran in patients with chronic dizziness

Journal of Vestibular Research-Equilibrium & Orientation, 2016
BACKGROUND: Psychiatric comorbidities are an important issue in the treatment of chronic dizziness patients. OBJECTIVE: To test the correlation between psychiatric status and subjective handicaps and to examine the effects of milnacipran on handicaps ...
A. Horii, T. Imai, T. Kitahara, A. Uno, Y. Morita, Kuniyuki Takahashi, H. Inohara   +6 more
semanticscholar   +1 more source

Die klinische Anwendung von Milnacipran in Österreich und Deutschland

Nervenheilkunde, 2019
Zusammenfassung Milnacipran ist ein Antidepressivum aus der Gruppe der Serotonin-Noradrenalin-Wiederaufnahmehemmer, zu welcher auch Venlafaxin und Duloxetin gehören.
M. Hienert, P. Ritter, M. Bauer, R. Lanzenberger, S. Kasper   +4 more
semanticscholar   +1 more source

Add-on Milnacipran Boosts Methylphenidate Response in an Adolescent With Attention-Deficit/Hyperactivity Disorder With Comorbid Anxiety and Enuresis.

American Journal of Therapeutics, 2019
generally well controlled after switching from DFXDT to DFX-G. This finding indicates that the DFX formulation can be switched without a loss of efficacy if appropriate doses are used.
Ahmed Naguy, Dalal H Elsori, Dalal Alawadhi, B. Alamiri   +3 more
semanticscholar   +1 more source

Drug-drug eutectic mixtures of celecoxib with tapentadol and milnacipran which could improve analgesic and antidepressant efficacy

Journal of Drug Delivery Science and Technology, 2022
Zhengge Yang, Ru Ma, Yin Chen, Yifang Zhang, Xin Liu, Bifeng Liu, Guisen Zhang, Chao Hao   +7 more
semanticscholar   +1 more source

The anticataplectic and REM suppression effect of milnacipran, an SNRI, on human and canine narcolepsy

Sleep and Biological Rhythms, 2021
Yoshihiko Kaneko, Y. Inoue, N. Fujiki, G. Han, S. Nishino, T. Shimizu, T. Kanbayashi, H. Kondo   +7 more
semanticscholar   +2 more sources

Milnacipran

Reactions Weekly, 2012
  +4 more sources

Milnacipran

Reactions Weekly, 2022
openaire   +1 more source